Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease.
Bénardeau A, Kahnert A, Schomber T, Meyer J, Pavkovic M, Kretschmer A, Lawrenz B, Hartmann E, Mathar I, Hueser J, Kraehling JR, Eitner F, Hahn MG, Stasch JP, Sandner P.
Bénardeau A, et al. Among authors: hartmann e.
Naunyn Schmiedebergs Arch Pharmacol. 2021 Dec;394(12):2363-2379. doi: 10.1007/s00210-021-02149-4. Epub 2021 Sep 22.
Naunyn Schmiedebergs Arch Pharmacol. 2021.
PMID: 34550407
Free PMC article.